Royalty Financing: The Alternative Credit Structure Retail Investors Rarely See

Royalty financing is a distinct private-credit structure in which an investor provides upfront capital to a company in exchange for a contractual percentage of that company's future revenue or royalty stream, rather than taking equity or charging fixed-rate interest. As of mid-2026, private credit has surpassed $1.3 trillion in actively deployed capital across the United States, and royalty-based structures now sit at the more differentiated edge of that market, offering cash-flow-linked returns that most retail investors never see. This piece breaks down how the asset class works, where it appears across industries, and how accredited investors can access it today.

What Royalty Financing Actually Is

Strip away the jargon and the core mechanic is straightforward. A company needs capital but does not want to dilute shareholders or take on fixed-payment debt. An investor provides that capital. In return, the investor receives a percentage of the company's gross or net revenue, every month or quarter, until either a defined multiple of the original investment is repaid (the "cap") or a fixed term expires. That percentage is the royalty.

The structure sits between debt and equity in the capital stack. Unlike a senior secured loan, there are no covenants, no scheduled amortization, and no collateral in the traditional sense. Unlike equity, there is no ownership stake and no participation in a potential exit. What you own is a contractual right to revenue, which in legal terms is a form of intangible asset or financial royalty.

Three variables drive the economics for investors. First, the royalty rate, typically expressed as a percentage of top-line revenue, often ranging from 2% to 8% depending on the sector and the perceived risk of the revenue stream. Second, the cap multiple, which defines the total amount the investor collects before the royalty obligation terminates (a 1.5x cap on a $1 million investment means the investor collects $1.5 million total). Third, the term or maturity, which may run anywhere from 12 months to the economic life of a patent or drug.

The implied yield to an investor depends heavily on how fast the underlying revenue grows. A company generating $20 million per year in revenue paying a 3% royalty delivers $600,000 annually to the royalty holder on a $5 million investment. That is a 12% annual yield assuming revenue stays flat. If revenue climbs to $30 million, the same royalty pays $900,000, a yield of 18% on the original cost. The math rewards investors when the businesses they back grow.

Pharma Royalties: The Largest and Most Developed Segment

Healthcare royalties are the most institutionally developed version of this structure. The business model works because drug royalties arise naturally from licensing and collaboration agreements. When a university, biotech, or researcher licenses a compound to a large pharmaceutical company, the licensor typically retains a royalty on net sales. That royalty stream, which may run for decades tied to patent life, can then be sold to a third party for upfront cash.

Royalty Pharma (Nasdaq: RPRX) is the dominant buyer of those streams. The company, which went public in June 2020, has deployed more than $16 billion acquiring royalties across 56 products spanning 68 distinct disease areas, according to its August 2026 corporate presentation. Its portfolio includes royalties on blockbuster drugs in cystic fibrosis, multiple sclerosis, and oncology, among other categories. The company targets a cost of capital around 7-8% and carries investment-grade debt at a blended coupon of approximately 3.1%, generating a meaningful spread.

Beyond acquiring existing royalties, Royalty Pharma creates what it calls "synthetic royalties." In this version, a biotech company grants a newly created royalty interest directly to Royalty Pharma in exchange for development or commercialization capital. The drug does not need an existing licensor. The biotech retains full operational control and avoids equity dilution. Royalty Pharma receives a contractual cut of future sales. Both sides argue they get a better deal than they would through a standard equity raise or a traditional debt facility, because a royalty structure carries no financial covenants and no fixed repayment pressure.

For retail-accessible exposure, RPRX shares trade on Nasdaq and pay a quarterly dividend. The stock effectively gives investors a diversified royalty portfolio spanning more than 35 approved products without the illiquidity of a private fund or the minimum investment requirements of a direct deal.

Mining and Natural Resources: Royalties as a Capital Formation Tool

The mining industry developed a parallel royalty tradition long before pharma. A net smelter return (NSR) royalty gives the holder a percentage of the revenue a mine operator receives when it sells processed ore. Those royalties are registered on property title and, in many jurisdictions, survive a mine operator's bankruptcy, which makes them structurally senior in certain respects to unsecured debt.

Franco-Nevada (NYSE/TSX: FNV) is the model the industry follows. The company does not operate mines. It acquires royalties and streams on producing mines, advanced projects, and exploration properties, then collects cash as operators extract ore. According to Franco-Nevada's 2026 Asset Handbook, the company delivered 519,000 gold-equivalent ounces in 2025 actuals and targets 555,000 to 615,000 for 2030, with approximately $3.1 billion in available capital to deploy in additional royalty and stream transactions. The company has raised its dividend for 17 consecutive years.

A metal stream is a close relative of a royalty. The streamer pays an upfront sum to a mine developer in exchange for the right to purchase a percentage of future gold or silver production at a fixed, below-market price per ounce. Wheaton Precious Metals (NYSE: WPM) is the largest pure-play streaming company by market capitalization. Both FNV and WPM provide publicly traded vehicles for investors seeking royalty-like exposure in natural resources, with liquidity, quarterly distributions, and balance sheets that do not carry operational mine risk.

The appeal to mining companies mirrors the pharma case. A copper miner developing a new deposit needs construction capital but may not want more dilutive equity. Selling a gold or silver stream from its own by-product output raises cash at a lower effective cost than a secondary equity offering, while the operator retains full control of copper revenue.

Revenue-Based Financing for Growth Companies

The most direct application of royalty logic to private businesses is revenue-based financing (RBF). Here, a lender advances capital to a growth-stage company, typically a SaaS startup or consumer brand, and receives a fixed percentage of monthly gross revenue until a defined repayment cap is reached. There is no maturity date in the traditional sense; payments rise when revenue rises and fall when revenue falls, which makes the structure inherently flexible for the borrower.

Lighter Capital, founded in 2010, pioneered this model for B2B SaaS companies and has deployed over $500 million across more than 1,200 financing rounds. The minimum qualification is typically $200,000 in annual recurring revenue (ARR) with at least five paying customers. Lighter Capital offers up to $10 million per round with no equity, no board seats, and no personal guarantees, using historical revenue metrics to underwrite rather than credit scores or pitch decks.

Founderpath targets a similar market, offering revenue financing for software companies with $1 million to $3 million in ARR, with the repayment percentage fluctuating based on actual monthly receipts rather than fixed installments. Clearco focuses on e-commerce operators, providing non-dilutive capital up to $10 million with payment terms up to 12 months, no collateral, and no all-asset lien, making it compatible with other lenders in a broader capital stack.

From the investor's perspective, these platforms primarily fund their loan books through institutional credit facilities. Retail accredited investors cannot directly participate in individual revenue-based deals through most of these operators. The investor-facing access point is a separate category entirely.

How Accredited Investors Access Royalty Financing Today

There are four practical paths into this asset class, each with different risk, liquidity, and minimum investment profiles.

Publicly traded royalty companies. RPRX, FNV, and WPM all trade on major exchanges. The entry barrier is a single share. These are the most liquid expression of royalty economics available to any investor. They carry management fees, corporate overhead, debt, and public market price volatility, so they do not deliver pure royalty exposure, but they are the most accessible.

Private credit platforms. Percent.com markets itself as the leading platform bringing private credit to accredited investors from a $500 minimum. The platform lists individual private credit deals, including royalty-backed notes, with maturities from 6 to 36 months and uses a Dutch auction model for price discovery. According to Percent's platform disclosures, accredited investor status is required under SEC regulations, verified at account opening, and deals span asset-backed lending structures across multiple sectors. This platform provides shorter duration access to private credit including royalty-adjacent instruments at minimums far below what traditional private credit funds require.

Specialty private funds. A number of registered investment advisers run funds specifically targeting life sciences royalties, pharmaceutical royalty monetization, or broader revenue-based financing portfolios. These are typically structured as closed-end funds or limited partnerships with minimum investments of $250,000 or higher and illiquidity periods of three to seven years. Access often requires a relationship with a broker-dealer or RIA. The trade-off for the illiquidity is potential for less correlated returns and exposure to deal flow that does not reach public markets.

Direct co-investment alongside platforms. Some revenue-based financing operators, including certain Reg D funds built on top of RBF lending, allow accredited investors to participate in pools of revenue-share agreements with individual companies. These carry the highest concentration risk, the least liquidity, and the most direct exposure to whether a specific portfolio of businesses performs. They also potentially carry the highest gross return if the underlying companies grow rapidly.

The Honest Caveat: What Can Go Wrong

Royalty financing and revenue-based structures carry a category of risk that fixed-rate debt does not. Your return is entirely performance-dependent. If the pharmaceutical product faces generic competition earlier than expected, the royalty stream drops. If the SaaS company churns customers or misses its ARR targets, the revenue-share payments slow. If the mine operator suspends production, the NSR royalty pays nothing until the mine restarts.

There is no principal protection. Unlike a senior secured loan with a lien on hard assets, most royalty instruments are not recoverable in a liquidation. A royalty on drug sales is worthless if the drug is withdrawn. A revenue share against a company that goes to zero returns zero.

Structural subordination is a second concern. In a stressed scenario, secured lenders and trade creditors will collect before royalty holders in most deal structures. A royalty is contractually senior to equity but typically junior to secured debt in a restructuring context.

Revenue variability also introduces duration uncertainty. A cap structure projected to be reached in 36 months may take 60 months if the business underperforms, compressing your actual annualized return even if the nominal cap is eventually hit. Annualized cost-of-capital for revenue-based borrowers is often reported in the 15% to 30% range from the borrower's side, but realized investor yields depend entirely on realized revenue growth.

The asset class is not a bond substitute. It fits alongside private equity or high-yield credit as a return-seeking allocation, not as a replacement for fixed income. The downside if the revenue thesis fails is real and unhedged.

Frequently Asked Questions

How is a royalty different from a loan?

A loan carries a fixed interest rate, a scheduled repayment date, and typically some form of collateral. A royalty is a contractual right to receive a percentage of revenue over time. There is no interest rate, no fixed repayment schedule, and often no collateral. The royalty holder gets paid only as the business generates revenue, which means returns are variable and performance-dependent rather than contractually fixed.

Can a non-accredited investor access royalty financing investments?

Currently, most royalty and revenue-based financing investment products available to individuals require accredited investor status under SEC Regulation D or similar exemptions. The practical exception is publicly traded royalty companies such as Royalty Pharma (RPRX), Franco-Nevada (FNV), and Wheaton Precious Metals (WPM), which any investor can purchase through a standard brokerage account as exchange-listed shares.

What return should an investor expect from a royalty financing structure?

Return depends entirely on the specific deal terms and the underlying business performance. Implied yields on revenue-based financing deals are often projected in the 12% to 25% annualized range at time of origination, but actual realized returns can be meaningfully lower if revenue growth is slower than underwritten, or higher if the business outperforms. Publicly traded royalty companies like RPRX have targeted portfolio receipts growth of more than 10% annually through 2030, with distributions paid quarterly.

Are royalty payments taxed differently than interest income?

Tax treatment varies by structure, jurisdiction, and whether the royalty is classified as ordinary income, return of capital, or a capital gain. Royalty income from publicly traded companies in pass-through or similar structures may receive preferential treatment in some cases, while direct royalty receipts from private arrangements are generally taxed as ordinary income. Consult a tax adviser before committing capital, as the specific structure of each instrument drives the tax outcome, and generalizations here are unreliable.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.